Preclinical and early clinical data demonstrate promising anti-tumor efficacy of CAR-NK cells targeting BCMA, CD19, and other tumor-associated antigens, with a lower incidence of graft-versus-host disease (GVHD) relative to allogeneic CAR-T therapies (34, 37–39). The gene discussed is TNFRSF17; the disease is graft versus host disease.